May Sanaee
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
May Sanaee has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
Terry Lee
Centre for Health Evaluation and Outcome Sciences, University of British Columbia, Vancouver, Canada
3 shared publicationsJohanne Sabourin
JS PT Corporation, Vancouver, BC
2 shared publicationsRoxana Geoffrion
Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
2 shared publications- Alain Y. Dury
Cosette Pharmaceuticals, Inc, Bridgewater, NJ
1 shared publication Alana Lazareck-Devlin
Lifemark Health Canada, Calgary, AB
1 shared publication- Alyssa Yee
Scripps Green Hospital, San Diego, CA
1 shared publication
Latest Publications
- Open Access
- 7 January 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (3) , 217-227
Prevalence of urinary tract infections in women with vulvovaginal atrophy and the impact of vaginal prasterone on the rate of urinary tract infections
Objective: The aims of this study were to assess the prevalence of urinary tract infections (UTI) in women newly diagnosed with vulvovaginal atrophy (VVA) versus women without VVA and to evaluate the potential of vaginal prasterone to be used in postmenopausal VVA women with UTI as prophylaxis to reduce the future UTI risk. As a first subgroup analysis, women using aromatase inhibitors, medications that stop the production of estrogen were analyzed. As a second subgroup analysis, we looked at women with diabetes to investigate whether the same prophylaxis approach should be considered. Methods: This observational retrospective inception cohort study was conducted using the Integrated Dataverse open-source claims database with data from February 2015 through January 2020. Results: A total of 22,245 women treated with prasterone for a minimum of 12 weeks were matched to women without any prescribed VVA-related treatment. Overall, women treated with prasterone have a significantly lower UTI prevalence compared to those untreated (6.58% vs 12.3%; P < 0.0001). The highest difference in UTI prevalence among the prasterone treated and untreated women was observed in those aged 65‐74 (7.15% vs 16.2%; P < 0.0001). Among aromatase inhibitor users and women with diabetes, those treated with prasterone have a significantly lower UTI prevalence (4.90% vs 9.79%; P < 0.01 and 14.59% vs 20.48%; P < 0.0001, respectively). Conclusions: This study suggests that intravaginal prasterone may be a good candidate for prophylaxis in postmenopausal women with UTI to reduce future UTI risk, including for women taking aromatase inhibitors and women with diabetes. This study is based on real-world evidence and warrants further investigation in a clinical setting.
- 7 January 2025
- Published by Wolters Kluwer Health in Menopause
- Vol. 32 (3) , 217-227
Open AccessPrevalence of urinary tract infections in women with vulvovaginal atrophy and the impact of vaginal prasterone on the rate of urinary tract infections
Objective: The aims of this study were to assess the prevalence of urinary tract infections (UTI) in women newly diagnosed with vulvovaginal atrophy (VVA) versus women without VVA and to evaluate the potential of vaginal prasterone to be used in postmenopausal VVA women with UTI as prophylaxis to reduce the future UTI risk. As a first subgroup analysis, women using aromatase inhibitors, medications that stop the production of estrogen were analyzed. As a second subgroup analysis, we looked at women with diabetes to investigate whether the same prophylaxis approach should be considered. Methods: This observational retrospective inception cohort study was conducted using the Integrated Dataverse open-source claims database with data from February 2015 through January 2020. Results: A total of 22,245 women treated with prasterone for a minimum of 12 weeks were matched to women without any prescribed VVA-related treatment. Overall, women treated with prasterone have a significantly lower UTI prevalence compared to those untreated (6.58% vs 12.3%; P < 0.0001). The highest difference in UTI prevalence among the prasterone treated and untreated women was observed in those aged 65‐74 (7.15% vs 16.2%; P < 0.0001). Among aromatase inhibitor users and women with diabetes, those treated with prasterone have a significantly lower UTI prevalence (4.90% vs 9.79%; P < 0.01 and 14.59% vs 20.48%; P < 0.0001, respectively). Conclusions: This study suggests that intravaginal prasterone may be a good candidate for prophylaxis in postmenopausal women with UTI to reduce future UTI risk, including for women taking aromatase inhibitors and women with diabetes. This study is based on real-world evidence and warrants further investigation in a clinical setting.
- Open Access
- 4 June 2024
- Published by Elsevier in Continence
- Vol. 11
Workshop on cultivating shared decision making to improve surgical outcomes for pelvic organ prolapse
- 4 June 2024
- Published by Elsevier in Continence
- Vol. 11
Open AccessWorkshop on cultivating shared decision making to improve surgical outcomes for pelvic organ prolapse
- 29 May 2024
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 46 (7) , 102565
CSPM Position Statement: The Landscape of Pelvic Health Physiotherapy in Canada
- 29 May 2024
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 46 (7) , 102565
CSPM Position Statement: The Landscape of Pelvic Health Physiotherapy in Canada
- 31 October 2019
- Published by Springer Nature in International Urogynecology Journal
- Vol. 31 (9) , 1821-1828
Urinary tract infection after clean-contaminated pelvic surgery: a retrospective cohort study and prediction model
Postoperative urinary tract infection (UTI) leads to increased patient morbidity and health care costs. A prediction model may identify patients at highest risk for UTI development. Our primary objective was to determine the rate of UTI in the first 6 weeks after benign gynecologic surgery. Our secondary objective was to identify risk factors and build a predictive model for postoperative UTI.
- 31 October 2019
- Published by Springer Nature in International Urogynecology Journal
- Vol. 31 (9) , 1821-1828
Urinary tract infection after clean-contaminated pelvic surgery: a retrospective cohort study and prediction model
Postoperative urinary tract infection (UTI) leads to increased patient morbidity and health care costs. A prediction model may identify patients at highest risk for UTI development. Our primary objective was to determine the rate of UTI in the first 6 weeks after benign gynecologic surgery. Our secondary objective was to identify risk factors and build a predictive model for postoperative UTI.
- 1 September 2019
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 41 (9) , 1268-1275.e4
Graduating Obstetrics and Gynaecology Residents’ Readiness for Practice: A Cross-Sectional Survey Study
- 1 September 2019
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 41 (9) , 1268-1275.e4
Graduating Obstetrics and Gynaecology Residents’ Readiness for Practice: A Cross-Sectional Survey Study
- 21 May 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 98 (12) , 1514-1522
Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta‐analysis
Introduction: Synthetic midurethral slings are the most common procedures currently performed for stress urinary incontinence in women. Infection is a frequent complication of urogynecologic surgery. We performed a systematic review and meta‐analysis to identify interventions that successfully prevent infections, including urinary tract infection (UTI) and/or bacteriuria, compared with no intervention, in women undergoing midurethral sling surgery with or without concomitant pelvic reconstructive procedures for prolapse.Material and methods: The primary outcome was the development of any infection post‐midurethral sling placement in women. MEDLINE, Embase, CINAHL and the Cochrane Library were searched for comparative studies from inception to July 2017, with no language restrictions. We used search terms related to midurethral sling, infections and infection‐reduction interventions. Two independent reviewers abstracted data and assessed study quality. Pooled effect size estimates were calculated. We conducted meta‐analysis of eligible studies. A protocol for this review has been registered and can be accessed online (http://hdl.handle.net/2429/64731).Results: We identified seven eligible studies of infection risk‐reducing interventions; all focused on UTIs. Only one study assessed preoperative antibiotics with midurethral sling alone and was halted early because of low UTI rates. All other studies (three randomized control trials and three observational studies) examined whether postoperative antibiotics decrease UTI/bacteriuria rates after midurethral sling with or without reconstructive procedures for pelvic organ prolapse and using bladder catheterization postoperatively. Due to considerable clinical heterogeneity, we only combined four studies for meta‐analysis. Postoperative oral prophylactic nitrofurantoin showed no significant benefit in reducing UTI/bacteriuria in women post‐midurethral sling with or without concomitant reconstructive pelvic surgery and the need for bladder catheterization, when compared with the reference group (pooled relative risk 0.73, 95% confidence interval [CI] 0.42‐1.25).Conclusions: Based on the best available evidence, postoperative oral nitrofurantoin is not effective at reducing UTI/bacteriuria rates in catheterized women after midurethral sling with or without concomitant pelvic reconstructive surgery for prolapse. For midurethral sling alone, preoperative antibiotic prophylaxis may not be needed for UTI prevention.
- 21 May 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 98 (12) , 1514-1522
Urinary tract infection prevention after midurethral slings in pelvic floor reconstructive surgery: A systematic review and meta‐analysis
Introduction: Synthetic midurethral slings are the most common procedures currently performed for stress urinary incontinence in women. Infection is a frequent complication of urogynecologic surgery. We performed a systematic review and meta‐analysis to identify interventions that successfully prevent infections, including urinary tract infection (UTI) and/or bacteriuria, compared with no intervention, in women undergoing midurethral sling surgery with or without concomitant pelvic reconstructive procedures for prolapse.Material and methods: The primary outcome was the development of any infection post‐midurethral sling placement in women. MEDLINE, Embase, CINAHL and the Cochrane Library were searched for comparative studies from inception to July 2017, with no language restrictions. We used search terms related to midurethral sling, infections and infection‐reduction interventions. Two independent reviewers abstracted data and assessed study quality. Pooled effect size estimates were calculated. We conducted meta‐analysis of eligible studies. A protocol for this review has been registered and can be accessed online (http://hdl.handle.net/2429/64731).Results: We identified seven eligible studies of infection risk‐reducing interventions; all focused on UTIs. Only one study assessed preoperative antibiotics with midurethral sling alone and was halted early because of low UTI rates. All other studies (three randomized control trials and three observational studies) examined whether postoperative antibiotics decrease UTI/bacteriuria rates after midurethral sling with or without reconstructive procedures for pelvic organ prolapse and using bladder catheterization postoperatively. Due to considerable clinical heterogeneity, we only combined four studies for meta‐analysis. Postoperative oral prophylactic nitrofurantoin showed no significant benefit in reducing UTI/bacteriuria in women post‐midurethral sling with or without concomitant reconstructive pelvic surgery and the need for bladder catheterization, when compared with the reference group (pooled relative risk 0.73, 95% confidence interval [CI] 0.42‐1.25).Conclusions: Based on the best available evidence, postoperative oral nitrofurantoin is not effective at reducing UTI/bacteriuria rates in catheterized women after midurethral sling with or without concomitant pelvic reconstructive surgery for prolapse. For midurethral sling alone, preoperative antibiotic prophylaxis may not be needed for UTI prevention.
- 21 December 2018
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (2) , 696-702
Pelvic floor hypertonicity in women with pelvic floor disorders: A case control and risk prediction study
Aim: Myofascial pelvic pain is a chronic and debilitating condition, sometimes associated with pelvic floor disorders (PFD) such as urinary incontinence, defecatory dysfunction or pelvic organ prolapse. Our aim was to identify risk factors in women with PFD and hypertonic pelvic floor, compared to controls without hypertonicity.Methods: Case control study (2009‐2017) of patients with PFD and a diagnosis of hypertonic pelvic floor. Cases were matched with patients who presented with the same PFD but without pelvic floor hypertonicity. Postoperative patients with hypertonic pelvic floor were matched with patients who underwent surgery for the same PFD but did not develop pain. Risk factors were compared between groups.Results: Ninety‐five cases were matched; 71% had urogynecologic surgery as a possible trigger for myofascial pain. Most were post‐menopausal. Overall, case patients were younger than controls (mean 54 vs 59, P = 0.002). Multivariate logistic regression identified risk factors of younger age (OR 1.45, 95%CI 1.04‐2.07), history of depression (OR 3, 95%CI 1.03‐9.09), musculoskeletal spine injury (OR 4.32, 95%CI 1.01‐21.26) and transobturator midurethral sling (OR 8.36, 95%CI 2.68‐31.32). Retropubic midurethral sling was protective against pelvic floor hypertonicity (OR 0.37, 95%CI 0.15‐0.86). A clinical prediction model including depression, endometriosis, irritable bowel, spine injury and type of midurethral sling was developed to estimate the probability for myofascial pain after urogynecologic surgery.Conclusions: Specific risk factors predispose women with PFD to chronic pelvic floor hypertonicity. Knowledge of these can help with patient counselling and choice of midurethral sling prior to PFD surgery.
- 21 December 2018
- Published by Wiley in Neurourology and Urodynamics
- Vol. 38 (2) , 696-702
Pelvic floor hypertonicity in women with pelvic floor disorders: A case control and risk prediction study
Aim: Myofascial pelvic pain is a chronic and debilitating condition, sometimes associated with pelvic floor disorders (PFD) such as urinary incontinence, defecatory dysfunction or pelvic organ prolapse. Our aim was to identify risk factors in women with PFD and hypertonic pelvic floor, compared to controls without hypertonicity.Methods: Case control study (2009‐2017) of patients with PFD and a diagnosis of hypertonic pelvic floor. Cases were matched with patients who presented with the same PFD but without pelvic floor hypertonicity. Postoperative patients with hypertonic pelvic floor were matched with patients who underwent surgery for the same PFD but did not develop pain. Risk factors were compared between groups.Results: Ninety‐five cases were matched; 71% had urogynecologic surgery as a possible trigger for myofascial pain. Most were post‐menopausal. Overall, case patients were younger than controls (mean 54 vs 59, P = 0.002). Multivariate logistic regression identified risk factors of younger age (OR 1.45, 95%CI 1.04‐2.07), history of depression (OR 3, 95%CI 1.03‐9.09), musculoskeletal spine injury (OR 4.32, 95%CI 1.01‐21.26) and transobturator midurethral sling (OR 8.36, 95%CI 2.68‐31.32). Retropubic midurethral sling was protective against pelvic floor hypertonicity (OR 0.37, 95%CI 0.15‐0.86). A clinical prediction model including depression, endometriosis, irritable bowel, spine injury and type of midurethral sling was developed to estimate the probability for myofascial pain after urogynecologic surgery.Conclusions: Specific risk factors predispose women with PFD to chronic pelvic floor hypertonicity. Knowledge of these can help with patient counselling and choice of midurethral sling prior to PFD surgery.
- Open Access
- 1 May 2017
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 39 (5) , 400-401
O-GYN-MD-112 Canadian Obstetrics and Gynaecology Residents: Are They Ready for Independent Practice?
- 1 May 2017
- Published by Elsevier in Journal of Obstetrics and Gynaecology Canada
- Vol. 39 (5) , 400-401
Open AccessO-GYN-MD-112 Canadian Obstetrics and Gynaecology Residents: Are They Ready for Independent Practice?